A Phase 1 Study of [14C]- IXAZOMIB (MLN9708) to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphomas

Trial Profile

A Phase 1 Study of [14C]- IXAZOMIB (MLN9708) to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphomas

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs Ixazomib (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 09 Oct 2015 Planned End Date changed from 1 Aug 2015 to 1 Mar 2016, according to ClinicalTrials.gov record.
    • 19 Mar 2015 Planned End Date changed from 1 Aug 2014 to 1 Aug 2015 as reporetd by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top